Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Effectiveness of two stroke-prevention procedures vary by age, say researchers

A published report provides the final details on how two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, though their effectiveness does vary by age, say researchers at the University of Alabama at Birmingham School of Public Health in collaboration with other North American stroke investigators.

29 May 2010

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

A published report provides the final details on how two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, though their effectiveness does vary by age, say researchers at the University of Alabama at Birmingham (UAB) School of Public Health in collaboration with other North American stroke investigators.

28 May 2010

CREST: Carotid artery surgery and stenting have long-term outcomes for patients with stroke

Physicians now have two safe and effective options to treat their patients at risk for stroke, says a researcher at Mayo Clinic who led a large, NIH-funded, national clinical trial testing surgery or use of a stent to open a blocked carotid artery.

28 May 2010

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased coronary tissue and guide therapeutic interventions, today announced that its next-generation LipiScan IVUS Coronary Imaging System will be featured at EuroPCR 2010, an international educational conference focused on introducing the latest techniques, updates and breakthrough science to the interventional cardiology community.

27 May 2010

CREST study data published in The New England Journal of Medicine

Data from the CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) study were published today in The New England Journal of Medicine. In this trial, stenting and surgery had similar initial safety and longer-term outcomes for symptomatic and asymptomatic men and women. Adverse event rates of death, stroke and heart attack were also similar for both therapies.

27 May 2010

Infants born with complex congenital heart disease also at risk for life-threatening gastrointestinal diseases

Infants born with complex congenital heart disease are not only at risk for serious heart-related complications, but also for developing a deadly bowel disease, regardless of the type of surgical intervention they receive for their heart. These are the findings from a study by Nationwide Children's Hospital, and appearing in Pediatric Critical Care Medicine published online May 6 ahead of print.

27 May 2010

Abbott's TREK Coronary Dilatation Catheter receives European approval

Abbott today announced the European approval and launch of its TREK™ Coronary Dilatation Catheter for the treatment of coronary artery disease. The TREK system represents a new approach to balloon catheter design, and provides physicians with a high-performing option for treating challenging lesions and difficult-to-reach blockages. Abbott received CE Mark for the TREK system earlier this year.

26 May 2010

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.

26 May 2010

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).

26 May 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.

26 May 2010

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.

26 May 2010

PIONEER trial evaluates new safe concept of stent-drug combination

Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

26 May 2010

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Boston Scientific Corporation today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research (ISR) study designed to compare the performance of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System to the XIENCE PRIME™ Everolimus-Eluting Coronary Stent System.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial.

25 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

MAQUET Cardiovascular commences enrollment in trial of FUSION and FUSION BIOLINE Vascular Grafts

MAQUET Cardiovascular LLC today announced enrollment of the first patient in FINEST (FUSION Vascular Graft, FUSION Vascular Graft with BIOLINE and EXXCEL SOFT ePTFE). This prospective, randomized, single-blind, three-arm, parallel group, multi-center study is evaluating the safety and efficacy of MAQUET's investigational FUSION Vascular Graft and FUSION BIOLINE Vascular Graft, compared with its commercially available EXXCEL Soft ePTFE Vascular Graft in peripheral artery bypass surgery.

25 May 2010

Boston Scientific collaborates with Philips, Siemens to offer integrated imaging systems

Boston Scientific Corporation today announced collaborations with Philips Healthcare and Siemens Medical Solutions to enable the use of its iLab® Ultrasound Imaging System with the Philips Allura™ Xper and the Siemens AXIOM™ Artis and Artis™ zee interventional X-ray systems. Intravascular ultrasound (IVUS) technology is designed to provide physicians a 360-degree view inside the heart and coronary vessels to assist with diagnosis and to generate a more accurate image of the diseased vessels than is possible with angiography alone.

From Philips Healthcare 25 May 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Stent News and Research

Further Reading

Effectiveness of two stroke-prevention procedures vary by age, say researchers

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

CREST: Carotid artery surgery and stenting have long-term outcomes for patients with stroke

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

CREST study data published in The New England Journal of Medicine

Infants born with complex congenital heart disease also at risk for life-threatening gastrointestinal diseases

Abbott's TREK Coronary Dilatation Catheter receives European approval

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

PIONEER trial evaluates new safe concept of stent-drug combination

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

MAQUET Cardiovascular commences enrollment in trial of FUSION and FUSION BIOLINE Vascular Grafts

Boston Scientific collaborates with Philips, Siemens to offer integrated imaging systems

DAPT Study expands into seven countries in the EU: HCRI

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News